---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-009462"
form_type: "8-K"
ticker: "CELU"
cik: "0001752828"
company_name: "Celularity Inc"
filed_at: "2025-05-09T23:59:59+00:00"
generated_at: "2026-05-22T01:56:20.838752+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Celularity reports 2024 revenue of $54.2M, up 138% YoY; operating loss narrows 80%

## Summary
- Net revenues $54.2M, up 138.1% YoY; product sales in wound care up 168.7% to $35.3M.
- Operating expenses fell 57% to $92.6M; loss from operations improved 80.1% to $38.4M.
- Received FDA Tissue Reference Group recommendation letters for new placental-derived biomaterial products.
- Cash and cash equivalents $738K at Dec 31, 2024, up from $227K prior year.
- Total assets $132.7M; stockholders' equity $8.8M at year-end 2024.

## SEC filing metadata
- accession: 0001641172-25-009462
- form_type: 8-K
- ticker: CELU
- cik: 0001752828
- company_name: Celularity Inc
- filed_at: 2025-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1752828/000164117225009462/0001641172-25-009462-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1752828/000164117225009462/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-009462
- JSON: https://secwatch.observer/filing/0001641172-25-009462.json
- Plain text: https://secwatch.observer/filing/0001641172-25-009462.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.